Occurrence of Pneumocystis Pneumonia in HIV-Infected Patients and the Interference of the HAART
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130315210107im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
From the beginning of the AIDS epidemic, pulmonary pneumocystosis (PCP) has been distinguished as one of the most frequent opportunistic diseases with high morbid-mortality. As from 1996, the advent of the highly active antiretroviral therapy (HAART) has changed the characteristics of such epidemic by reducing its related diseases and, as a result, AIDS-related mortality. With the purpose to estimate PCP occurrence and HAART interference, 376 HIV-infected or AIDS patients were studied from January 1992 to December 2002.
Study Type: | Observational |
Study Design: | Observational Model: Case Control Time Perspective: Retrospective |
Official Title: | Occurrence of Pneumocystis Pneumonia in HIV-Infected Patients and the Interference of the Highly Active Antiretroviral Therapy |
Enrollment: | 376 |
Study Start Date: | February 2003 |
Study Completion Date: | February 2005 |
Groups/Cohorts |
---|
no HAART
Patients that no received HAART
|
with HAART
Patients that received HAART
|
Detailed Description:
From the beginning of the AIDS epidemic, pneumocystis pneumonia (PCP) has been distinguished as one of the most frequent opportunistic diseases with high morbid-mortality. As from 1996, the advent of the highly active antiretroviral therapy (HAART) has changed the characteristics of such epidemic by reducing its related diseases and, as a result, AIDS-related mortality. With the purpose to estimate PCP occurrence and HAART interference, 376 HIV-infected or AIDS patients were studied from January 1992 to December 2002. Among them, 58 (15.5%) PCP cases were found. There was a higher occurrence of PCP in the group of patients in which HAART was not used, with 40 (69.0%) of the episodes. As regards the studied period, a tendency to a linear reduction in annual PCP incidence was observed. The mean of T CD4+ lymphocytes in the patients with PCP (117 cells/mm3) was significantly lower when compared to that of the other individuals (325 cells/mm3). Therefore, this study suggests a temporal reduction in PCP occurrence related to HAART use with higher T CD4+ lymphocyte counts. Nevertheless, this opportunistic infection still shows significant incidence in AIDS patients.
![](https://webarchive.library.unt.edu/web/20130315210107im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
376 HIV-infected or AIDS patients were studied from January 1992 to December 2002
Inclusion Criteria:
- HIV infection
Exclusion Criteria:
- No HIV infection
![](https://webarchive.library.unt.edu/web/20130315210107im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Brazil | |
Faculdade de Medicina de Botucatu - Unesp | |
Botucatu, Sao Paulo, Brazil, 18618970 |
Principal Investigator: | Alexandre N Barbosa, MD, MSc | UPECLIN HC FM Botucatu Unesp |
![](https://webarchive.library.unt.edu/web/20130315210107im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
No publications provided
Responsible Party: | Sergio Muller, Faculdade de Medicina de Botucatu - Unesp |
ClinicalTrials.gov Identifier: | NCT00516581 History of Changes |
Other Study ID Numbers: | upeclin/HC/FMB-Unesp-13, PCP UnespFMB 2003 |
Study First Received: | August 14, 2007 |
Last Updated: | September 4, 2008 |
Health Authority: | Brazil: National Committee of Ethics in Research |
Keywords provided by UPECLIN HC FM Botucatu Unesp:
Pneumocystis Pneumonia Acquired Immune Deficiency Syndrome Highly Active Antiretroviral Therapy Treatment Experienced Treatment Naive |
Additional relevant MeSH terms:
Pneumonia Pneumonia, Pneumocystis Lung Diseases Respiratory Tract Diseases |
Respiratory Tract Infections Lung Diseases, Fungal Mycoses Pneumocystis Infections |
ClinicalTrials.gov processed this record on March 14, 2013